Literature DB >> 2939312

Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man.

T G Yandle, A M Richards, M G Nicholls, R Cuneo, E A Espiner, J H Livesey.   

Abstract

The disappearance and metabolic clearance rate (MCR) of alpha human atrial natriuretic peptide (alpha h-ANP) has been studied in normal man by radioimmunoassay of the atrial peptide in plasma and plasma extracts. After an intravenous (iv) bolus injection of 100 micrograms alpha h-ANP, levels of immunoreactive alpha h-ANP (IR-alpha hANP) in unextracted plasma fell rapidly and exponentially during the first 10 min (t1/2 = 2.5 min), after which levels declined more slowly to reach basal values 30 min after injection. Venous plasma extracts, purified by Sep Pak cartridges, were used to calculate the MCR of IR-alpha hANP under steady state conditions of constant iv infusion (200 micrograms over 60 min) in healthy volunteers. Calculated MCR from venous samples was 2.4 L/min and volume of distribution 10.7 L. After cessation of infusions, the disappearance rate (rapid phase) of IR-alpha hANP was 3.1 min. These studies show that alpha h-ANP is rapidly metabolized at rates similar to other vasoactive hormones such as angiotensin II and vasopressin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939312     DOI: 10.1016/0024-3205(86)90137-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  38 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure.

Authors:  H Meyer-Lehnert; T Bayer; H G Predel; K Glänzer; H J Kramer
Journal:  Klin Wochenschr       Date:  1991-11-26

Review 3.  A heart-adipose tissue connection in the regulation of energy metabolism.

Authors:  Sheila Collins
Journal:  Nat Rev Endocrinol       Date:  2013-12-03       Impact factor: 43.330

Review 4.  Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.

Authors:  Kailash N Pandey
Journal:  Can J Physiol Pharmacol       Date:  2011-08-04       Impact factor: 2.273

Review 5.  Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.

Authors:  O Vesterqvist; R A Reeves
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

6.  Inhibition of natriuretic peptide receptor 1 reduces itch in mice.

Authors:  Hans Jürgen Solinski; Patricia Dranchak; Erin Oliphant; Xinglong Gu; Thomas W Earnest; John Braisted; James Inglese; Mark A Hoon
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

7.  ANP is cleared much faster than BNP in patients with congestive heart failure.

Authors:  Kuniko Kimura; Yukinari Yamaguchi; Manabu Horii; Hiroyuki Kawata; Hiromitsu Yamamoto; Shiro Uemura; Yoshihiko Saito
Journal:  Eur J Clin Pharmacol       Date:  2007-05-04       Impact factor: 2.953

8.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.

Authors:  M Mukoyama; K Nakao; K Hosoda; S Suga; Y Saito; Y Ogawa; G Shirakami; M Jougasaki; K Obata; H Yasue
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

9.  Kinetics of atrial natriuretic peptide in young and elderly subjects.

Authors:  A C Tan; T L Jansen; E F Termond; F G Russel; T Thien; P W Kloppenborg; T J Benraad
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 10.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.